Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors

References

• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14(1):73. doi: 10.1186/s12916-016-0623-5
   PubMed Web of Science ®Google Scholar
• Weiner LM. Cancer immunotherapy–the endgame begins. N Engl J Med. 2008;358(25):2664–2665. doi: 10.1056/NEJMp0803663
   PubMed Web of Science ®Google Scholar
• Couzin-Frankel J. Cancer Immunotherapy. Science. 2013;342(6165): 1432–1433.
   PubMed Web of Science ®Google Scholar
• Chevolet I, Speeckaert R, Schreuer M, et al. Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. Oncoimmunology. 2015;4(3):e982382. doi: 10.4161/2162402X.2014.982382
   PubMed Web of Science ®Google Scholar
• Edwards SC, Hoevenaar WHM, Coffelt SB. Emerging immunotherapies for metastasis. Br J Cancer. 2021;124(1):37–48. doi: 10.1038/s41416-020-01160-5
   PubMed Web of Science ®Google Scholar
• Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol. 2012;23 Suppl 8(Suppl 8):viii6–9. doi: 10.1093/annonc/mds256
   PubMedGoogle Scholar
• Twomey JD, Zhang B. Cancer immunotherapy update: FDA-Approved checkpoint inhibitors and companion diagnostics. Aaps J. 2021;23(2):39. doi: 10.1208/s12248-021-00574-0
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Iqbal F. CTLA-4 blockade: therapeutic potential in cancer treatments. Onco Targets Ther. 2010;3:15–25. doi: 10.2147/OTT.S4833
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Matsumura N, et al. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol. 2016;21(3):462–473. doi: 10.1007/s10147-016-0959-z
   PubMed Web of Science ®Google Scholar
• Patsoukis N, Wang Q, Strauss L, et al. Revisiting the PD-1 pathway. Sci Adv. 2020;6(38): doi: 10.1126/sciadv.abd2712
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Hatabu H, et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655–668. doi: 10.1038/nrclinonc.2017.88
   PubMed Web of Science ®Google Scholar
• Chen Q, Sun T, Jiang C. Recent advancements in nanomedicine for ‘cold’ tumor immunotherapy. Nanomicro Lett. 2021;13(1):92. doi: 10.1007/s40820-021-00622-6
   PubMed Web of Science ®Google Scholar
• Haanen JBAG. Converting cold into hot tumors by combining immunotherapies. Cell. 2017;170(6):1055–1056. doi: 10.1016/j.cell.2017.08.031
   PubMed Web of Science ®Google Scholar
• Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat Rev Drug Discov. 2019;18(3):197–218.
   PubMed Web of Science ®Google Scholar
• Li Y, Xiang S, Pan W, et al. Targeting tumor immunosuppressive microenvironment for pancreatic cancer immunotherapy: Current research and future perspective. Front Oncol. 2023;13. doi: 10.3389/fonc.2023.1166860
   Web of Science ®Google Scholar
• Shim MK, Yang S, Sun IC, et al. Tumor-activated carrier-free prodrug nanoparticles for targeted cancer immunotherapy: preclinical evidence for safe and effective drug delivery. Adv Drug Deliv Rev. 2022;183:183.
   Web of Science ®Google Scholar
• Gondhowiardjo SA, Handoko, Jayalie VF, et al. Tackling resistance to cancer immunotherapy: what do we know? Molecules. 2020;25(18):4096. doi: 10.3390/molecules25184096
   PubMed Web of Science ®Google Scholar
• van den Elsen PJ, Holling TM, van der Stoep N, et al. DNA methylation and expression of major histocompatibility complex class I and class II transactivator genes in human developmental tumor cells and in T cell malignancies. Clin Immunol. 2003;109(1):46–52. doi: 10.1016/S1521-6616(03)00200-6
   PubMed Web of Science ®Google Scholar
• Yoshihama S, Roszik J, Downs I, et al. NLRC5/MHC class I transactivator is a target for immune evasion in cancer. Proc Natl Acad Sci U S A. 2016;113(21):5999–6004. doi: 10.1073/pnas.1602069113
   PubMed Web of Science ®Google Scholar
• Kriegsman BA, Vangala P, Chen BJ, et al. Frequent loss of IRF2 in cancers leads to immune evasion through decreased MHC class I antigen presentation and increased PD-L1 expression. J Immunol. 2019;203(7):1999–2010. doi: 10.4049/jimmunol.1900475
   PubMed Web of Science ®Google Scholar
• Luo N, Nixon MJ, Gonzalez-Ericsson PI, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. Nat Commun. 2018;9(1):248. doi: 10.1038/s41467-017-02630-w
   PubMed Web of Science ®Google Scholar
• Chen Y, Song Y, Du W, et al. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):78. doi: 10.1186/s12929-019-0568-z
   PubMed Web of Science ®Google Scholar
• Lamb MG, Rangarajan HG, Tullius BP, et al. Natural killer cell therapy for hematologic malignancies: successes, challenges, and the future. Stem Cell Res Ther. 2021;12(1):211. doi: 10.1186/s13287-021-02277-x
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao X, Wan YY. Intricacies of TGF-β signaling in treg and Th17 cell biology. Cell Mol Immunol. 2023;20(9):1002–1022. doi: 10.1038/s41423-023-01036-7
   PubMedGoogle Scholar
• Li Y, Liu X, Zhang X, et al. Immunogenic cell death inducers for enhanced cancer immunotherapy. Chem Commun (Camb). 2021;57(91):12087–12097. doi: 10.1039/D1CC04604G
   PubMed Web of Science ®Google Scholar
• Hernandez C, Huebener P, Schwabe RF. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene. 2016;35(46):5931–5941. doi: 10.1038/onc.2016.104
   PubMed Web of Science ®Google Scholar
• Kepp O, Liu P, Zhao L, et al. Surface-exposed and soluble calreticulin: conflicting biomarkers for cancer prognosis. Oncoimmunology. 2020;9(1):1792037. doi: 10.1080/2162402X.2020.1792037
   PubMed Web of Science ®Google Scholar
• Ashrafizadeh M, Farhood B, Eleojo Musa A, et al. Damage-associated molecular patterns in tumor radiotherapy. Int Immunopharmacol. 2020;86:106761. doi: 10.1016/j.intimp.2020.106761
   PubMed Web of Science ®Google Scholar
• Park SY, Kim IS. Engulfment signals and the phagocytic machinery for apoptotic cell clearance. Exp Mol Med. 2017;49(5):e331. doi: 10.1038/emm.2017.52
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Kepp O, et al. Immunogenic cell death in cancer therapy. Annu Rev Immunol. 2013;31(1):51–72. doi: 10.1146/annurev-immunol-032712-100008
   PubMed Web of Science ®Google Scholar
• Sheridan C. IDO inhibitors move center stage in immuno-oncology. Nat Biotechnol. 2015;33(4):321–322. doi: 10.1038/nbt0415-321
   PubMed Web of Science ®Google Scholar
• Qi J, Jin F, Xu X, et al. Combination cancer immunotherapy of nanoparticle-based immunogenic cell death inducers and immune checkpoint inhibitors. Int J Nanomedicine. 2021;16:1435–1456. doi: 10.2147/IJN.S285999
   PubMed Web of Science ®Google Scholar
• Lim S, Park J, Shim MK, et al. Recent advances and challenges of repurposing nanoparticle-based drug delivery systems to enhance cancer immunotherapy. Theranostics. 2019;9(25):7906–7923. doi: 10.7150/thno.38425
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang G, Chen Y, et al. Immunogenic cell death in cancer therapy: present and emerging inducers. J Cell Mol Med. 2019;23(8):4854–4865. doi: 10.1111/jcmm.14356
   PubMed Web of Science ®Google Scholar
• Su YL, Hu SH. Functional nanoparticles for tumor penetration of therapeutics. Pharmaceutics. 2018;10(4):193. doi: 10.3390/pharmaceutics10040193
   PubMed Web of Science ®Google Scholar
• Du J, Lane LA, Nie S. Stimuli-responsive nanoparticles for targeting the tumor microenvironment. J Control Release. 2015;219:205–214. doi: 10.1016/j.jconrel.2015.08.050
   PubMed Web of Science ®Google Scholar
• Thierry B. Drug nanocarriers and functional nanoparticles: applications in cancer therapy. Curr Drug Deliv. 2009;6(4):391–403. doi: 10.2174/156720109789000474
   PubMedGoogle Scholar
• Kim J, Cho H, Lim DK, et al. Perspectives for improving the tumor targeting of nanomedicine via the EPR effect in clinical tumors. Int J Mol Sci. 2023;24(12):10082. doi: 10.3390/ijms241210082
   PubMed Web of Science ®Google Scholar
• Avgoustakis K, Beletsi A, Panagi Z, et al. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles. Int J Pharm. 2003;259(1–2):115–127. doi: 10.1016/S0378-5173(03)00224-2
   PubMed Web of Science ®Google Scholar
• Choi HS, Liu W, Misra P, et al. Renal clearance of quantum dots. Nat Biotechnol. 2007;25(10):1165–1170. doi: 10.1038/nbt1340
   PubMed Web of Science ®Google Scholar
• Shim MK, Song SK, Jeon SI, et al. Nano-sized drug delivery systems to potentiate the immune checkpoint blockade therapy. Expert Opin Drug Deliv. 2022;19(6):641–652. doi: 10.1080/17425247.2022.2081683
   PubMed Web of Science ®Google Scholar
• Ryu JH, Koo H, Sun IC, et al. Tumor-targeting multi-functional nanoparticles for theragnosis: new paradigm for cancer therapy. Adv Drug Deliv Rev. 2012;64(13):1447–1458. doi: 10.1016/j.addr.2012.06.012
   PubMed Web of Science ®Google Scholar
• Ding YN, Xue M, Tang QS, et al. Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: trends and challenges. World J Gastroenterol. 2022;28(37):5403–5419. doi: 10.3748/wjg.v28.i37.5403
   PubMed Web of Science ®Google Scholar
• Yang M, Zhang C, Wang R, et al. Cancer immunotherapy elicited by immunogenic cell death based on smart nanomaterials. Small Methods. 2023;7(5):e2201381. doi: 10.1002/smtd.202201381
   PubMed Web of Science ®Google Scholar
• Yhee JY, Son S, Lee H, et al. Nanoparticle-based combination therapy for cancer treatment. Curr Pharm Des. 2015;21(22):3158–3166. doi: 10.2174/1381612821666150531165059
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12(12):860–875. doi: 10.1038/nrc3380
   PubMed Web of Science ®Google Scholar
• Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ. 2014;21(1):39–49. doi: 10.1038/cdd.2013.84
   PubMed Web of Science ®Google Scholar
• Moserova I, Truxova I, Garg AD, et al. Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. Oncoimmunology. 2017;6(1):e1258505. doi: 10.1080/2162402X.2016.1258505
   PubMed Web of Science ®Google Scholar
• Garg AD, Dudek AM, Ferreira GB, et al. ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death. Autophagy. 2013;9(9):1292–1307. doi: 10.4161/auto.25399
   PubMed Web of Science ®Google Scholar
• Dewaele M, Martinet W, Rubio N, et al. Autophagy pathways activated in response to PDT contribute to cell resistance against ROS damage. J Cell Mol Med. 2011;15(6):1402–1414. doi: 10.1111/j.1582-4934.2010.01118.x
   PubMed Web of Science ®Google Scholar
• Buytaert E, Callewaert G, Hendrickx N, et al. Role of endoplasmic reticulum depletion and multidomain proapoptotic BAX and BAK proteins in shaping cell death after hypericin-mediated photodynamic therapy. Faseb J. 2006;20(6):756–758. doi: 10.1096/fj.05-4305fje
   PubMedGoogle Scholar
• van Vliet AR, Agostinis P. When under pressure, get closer: PERKing up membrane contact sites during ER stress. Biochem Soc Trans. 2016;44(2):499–504. doi: 10.1042/BST20150272
   PubMedGoogle Scholar
• Garg AD, Krysko DV, Verfaillie T, et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. Embo J. 2012;31(5):1062–1079. doi: 10.1038/emboj.2011.497
   PubMed Web of Science ®Google Scholar
• Fucikova J, Becht E, Iribarren K, et al. Calreticulin expression in human non-small cell lung cancers correlates with increased accumulation of antitumor immune cells and favorable prognosis. Cancer Res. 2016;76(7):1746–1756. doi: 10.1158/0008-5472.CAN-15-1142
   PubMed Web of Science ®Google Scholar
• Krysko DV, Agostinis P, Krysko O, et al. Emerging role of damage-associated molecular patterns derived from mitochondria in inflammation. Trends Immunol. 2011;32(4):157–164. doi: 10.1016/j.it.2011.01.005
   PubMed Web of Science ®Google Scholar
• Green DR, Ferguson T, Zitvogel L, et al. Immunogenic and tolerogenic cell death. Nat Rev Immunol. 2009;9(5):353–363. doi: 10.1038/nri2545
   PubMed Web of Science ®Google Scholar
• Clarke C, Smyth MJ. Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol. 2007;25(2):192–193. doi: 10.1038/nbt0207-192
   PubMed Web of Science ®Google Scholar
• Li D, Wu M. Pattern recognition receptors in health and diseases. Signal Transduct Target Ther. 2021;6(1):291. doi: 10.1038/s41392-021-00687-0
   PubMed Web of Science ®Google Scholar
• Anthoney N, Foldi I, Hidalgo A. Toll and toll-like receptor signalling in development. Development. 2018;145(9). doi: 10.1242/dev.156018
   PubMed Web of Science ®Google Scholar
• Satoh T, Akira S, Gordon S. Toll-like receptor signaling and its inducible proteins. Microbiol Spectr. 2016;4(6). doi: 10.1128/microbiolspec.MCHD-0040-2016
   PubMed Web of Science ®Google Scholar
• Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell. 2006;124(4):783–801. doi: 10.1016/j.cell.2006.02.015
   PubMed Web of Science ®Google Scholar
• Del Prete A, Salvi V, Soriani A, et al. Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol. 2023;20(5):432–447. doi: 10.1038/s41423-023-00990-6
   PubMed Web of Science ®Google Scholar
• Sun D, Zhang J, Wang L, et al. Nanodelivery of immunogenic cell death-inducers for cancer immunotherapy. Drug Discov Today. 2021;26(3):651–662. doi: 10.1016/j.drudis.2020.11.029
   PubMed Web of Science ®Google Scholar
• Minute L, Teijeira A, Sanchez-Paulete AR, et al. Cellular cytotoxicity is a form of immunogenic cell death. J Immunother Cancer. 2020;8(1):e000325. doi: 10.1136/jitc-2019-000325
   PubMed Web of Science ®Google Scholar
• Radogna F, Diederich M. Stress-induced cellular responses in immunogenic cell death: implications for cancer immunotherapy. Biochem Pharmacol. 2018;153:12–23. doi: 10.1016/j.bcp.2018.02.006
   PubMed Web of Science ®Google Scholar
• Ahmed A, Tait SWG. Targeting immunogenic cell death in cancer. Mol Oncol. 2020;14(12):2994–3006. doi: 10.1002/1878-0261.12851
   PubMed Web of Science ®Google Scholar
• Moon Y, Shim MK, Choi J, et al. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death. Theranostics. 2022;12(5):1999–2014. doi: 10.7150/thno.69119
   PubMed Web of Science ®Google Scholar
• Cho H, Shim MK, Yang S, et al. Cathepsin B-Overexpressed tumor cell activatable albumin-binding doxorubicin prodrug for cancer-targeted therapy. Pharmaceutics. 2021;14(1):83. doi: 10.3390/pharmaceutics14010083
   PubMed Web of Science ®Google Scholar
• Kim J, Shim MK, Cho YJ, et al. The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis. Biomaterials. 2021;279:121189. doi: 10.1016/j.biomaterials.2021.121189
   PubMed Web of Science ®Google Scholar
• Choi J, Shim MK, Yang S, et al. Visible-light-triggered prodrug nanoparticles combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. ACS Nano. 2021;15(7):12086–12098. doi: 10.1021/acsnano.1c03416
   PubMed Web of Science ®Google Scholar
• Yang S, Shim MK, Kim WJ, et al. Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity. Biomaterials. 2021;272:120791. doi: 10.1016/j.biomaterials.2021.120791
   PubMed Web of Science ®Google Scholar
• Kim J, Shim MK, Yang S, et al. Combination of cancer-specific prodrug nanoparticle with bcl-2 inhibitor to overcome acquired drug resistance. J Control Release. 2021;330:920–932. doi: 10.1016/j.jconrel.2020.10.065
   PubMed Web of Science ®Google Scholar
• Shim MK, Moon Y, Yang S, et al. Cancer-specific drug-drug nanoparticles of pro-apoptotic and cathepsin B-cleavable peptide-conjugated doxorubicin for drug-resistant cancer therapy. Biomaterials. 2020;261:120347. doi: 10.1016/j.biomaterials.2020.120347
   PubMed Web of Science ®Google Scholar
• Shim MK, Park J, Yoon HY, et al. Carrier-free nanoparticles of cathepsin B-cleavable peptide-conjugated doxorubicin prodrug for cancer targeting therapy. J Control Release. 2019;294:376–389. doi: 10.1016/j.jconrel.2018.11.032
   PubMed Web of Science ®Google Scholar
• Song S, Shim MK, Yang S, et al. All-in-one glycol chitosan nanoparticles for co-delivery of doxorubicin and anti-PD-L1 peptide in cancer immunotherapy. Bioact Mater. 2023;28:358–375. doi: 10.1016/j.bioactmat.2023.05.016
   PubMed Web of Science ®Google Scholar
• Na JH, Lee SY, Lee S, et al. Effect of the stability and deformability of self-assembled glycol chitosan nanoparticles on tumor-targeting efficiency. J Control Release. 2012;163(1):2–9. doi: 10.1016/j.jconrel.2012.07.028
   PubMed Web of Science ®Google Scholar
• Ryu JH, Yoon HY, Sun IC, et al. Tumor-targeting glycol chitosan nanoparticles for cancer heterogeneity. Adv Mater. 2020;32(51):e2002197. doi: 10.1002/adma.202002197
   PubMed Web of Science ®Google Scholar
• Yang S, Shim MK, Song S, et al. Liposome-mediated PD-L1 multivalent binding promotes the lysosomal degradation of PD-L1 for T cell-mediated antitumor immunity. Biomaterials. 2022;290:121841. doi: 10.1016/j.biomaterials.2022.121841
   PubMed Web of Science ®Google Scholar
• Tang K, Wu YH, Song Y, et al. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J Hematol Oncol. 2021;14(1):68. doi: 10.1186/s13045-021-01080-8
   PubMed Web of Science ®Google Scholar
• Zhang J, He X, Ma Y, et al. Overexpression of ROCK1 and ROCK2 inhibits human laryngeal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(1):244–251.
   PubMed Web of Science ®Google Scholar
• Zakharia Y, McWilliams RR, Rixe O, et al. Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma. J Immunother Cancer. 2021;9(6):e002057. doi: 10.1136/jitc-2020-002057
   PubMed Web of Science ®Google Scholar
• Labadie BW, Bao R, Luke JJ. Reimagining IDO pathway inhibition in cancer immunotherapy via downstream focus on the tryptophan-kynurenine-aryl hydrocarbon axis. Clin Cancer Res. 2019;25(5):1462–1471. doi: 10.1158/1078-0432.CCR-18-2882
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol. 2016;37(3):193–207. doi: 10.1016/j.it.2016.01.002
   PubMed Web of Science ®Google Scholar
• Quintana FJ, Murugaiyan G, Farez MF, et al. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A. 2010;107(48):20768–20773. doi: 10.1073/pnas.1009201107
   PubMed Web of Science ®Google Scholar
• Mezrich JD, Fechner JH, Zhang XJ, et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190–3198. doi: 10.4049/jimmunol.0903670
   PubMed Web of Science ®Google Scholar
• Fallarino F, Grohmann U, You S, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol. 2006;176(11):6752–6761. doi: 10.4049/jimmunol.176.11.6752
   PubMed Web of Science ®Google Scholar
• Kim S, Kim SA, Han J, et al. Rho-Kinase as a target for cancer therapy and its immunotherapeutic potential. Int J Mol Sci. 2021;22(23):12916. doi: 10.3390/ijms222312916
   PubMed Web of Science ®Google Scholar
• Ross SH, Cantrell DA. Signaling and function of interleukin-2 in T lymphocytes. Annu Rev Immunol. 2018;36(1):411–433. doi: 10.1146/annurev-immunol-042617-053352
   PubMed Web of Science ®Google Scholar
• Liu J, Zhao Z, Qiu N, et al. Co-delivery of IOX1 and doxorubicin for antibody-independent cancer chemo-immunotherapy. Nat Commun. 2021;12(1):2425. doi: 10.1038/s41467-021-22407-6
   PubMed Web of Science ®Google Scholar
• Wei J, Wu D, Shao Y, et al. ApoE-mediated systemic nanodelivery of granzyme B and CpG for enhanced glioma immunotherapy. JControlled Release. 2022;347:68–77. doi: 10.1016/j.jconrel.2022.04.048
   PubMed Web of Science ®Google Scholar
• Guo B, Qu Y, Sun Y, et al. Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative “cold” triple-negative breast cancer. Bioact Mater. 2023;25:61–72. doi: 10.1016/j.bioactmat.2023.01.014
   PubMed Web of Science ®Google Scholar
• Xia Y, Wei J, Zhao S, et al. Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma. J Controlled Release. 2021;336:262–273. doi: 10.1016/j.jconrel.2021.06.032
   PubMed Web of Science ®Google Scholar
• Shen F, Feng L, Zhu Y, et al. Oxaliplatin-/NLG919 prodrugs-constructed liposomes for effective chemo-immunotherapy of colorectal cancer. Biomaterials. 2021;255:120190. doi: 10.1016/j.biomaterials.2020.120190
   Web of Science ®Google Scholar
• Li Q, Liu J, Fan H, et al. IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment. Biomaterials. 2021;269:120388. doi: 10.1016/j.biomaterials.2020.120388
   PubMed Web of Science ®Google Scholar
• Mei KC, Liao YP, Jiang J, et al. Liposomal delivery of mitoxantrone and a cholesteryl indoximod prodrug provides effective chemo-immunotherapy in multiple solid tumors. ACS Nano. 2020;14(10):13343–13366. doi: 10.1021/acsnano.0c05194
   PubMed Web of Science ®Google Scholar
• Wu J, Tang C, Yin C. Co-delivery of doxorubicin and interleukin-2 via chitosan based nanoparticles for enhanced antitumor efficacy. Acta Biomater. 2017;47:81–90. doi: 10.1016/j.actbio.2016.10.012
   PubMed Web of Science ®Google Scholar
• Ye J, Hou B, Chen F, et al. Bispecific prodrug nanoparticles circumventing multiple immune resistance mechanisms for promoting cancer immunotherapy. Acta Pharm Sin B. 2022;12(6):2695–2709. doi: 10.1016/j.apsb.2021.09.021
   PubMed Web of Science ®Google Scholar
• Kim M, Lee JS, Kim W, et al. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression. J Control Release. 2022;348:893–910. doi: 10.1016/j.jconrel.2022.06.039
   PubMed Web of Science ®Google Scholar
• Liu Y, Xie J, Zhao X, et al. A polymeric IDO inhibitor based on poly(ethylene glycol)-b-poly(L-tyrosine-co-1-methyl-D-tryptophan) enables facile trident cancer immunotherapy. Biomater Sci. 2022;10(19):5731–5743. doi: 10.1039/D2BM01181F
   PubMed Web of Science ®Google Scholar
• Wang Z, Chen L, Ma Y, et al. Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal. J Nanobiotechnology. 2021;19(1):243. doi: 10.1186/s12951-021-00975-5
   PubMed Web of Science ®Google Scholar
• Sa LT, Albernaz Mde S, Patricio BF, et al. Biodistribution of nanoparticles: initial considerations. J Pharm Biomed Anal. 2012;70:602–604. doi: 10.1016/j.jpba.2012.06.008
   PubMed Web of Science ®Google Scholar
• Namiot ED, Sokolov AV, Chubarev VN, et al. Nanoparticles in clinical trials: analysis of clinical trials, FDA approvals and use for COVID-19 vaccines. Int J Mol Sci. 2023;24(1):787. doi: 10.3390/ijms24010787
   PubMed Web of Science ®Google Scholar
• Hani U, Gowda BHJ, Siddiqua A, et al. Herbal approach for treatment of cancer using curcumin as an anticancer agent: a review on novel drug delivery systems. J Mol Liq. 2023;390:390. doi: 10.1016/j.molliq.2023.123037
   Web of Science ®Google Scholar